Safety of perampanel in patients with motor neuron disease

Safety of perampanel in patients with motor neuron disease - Safety of perampanel in patients with motor neuron disease

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026221

Enrollment

Registered

2017-03-01

Start date

2017-03-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

amyotrophic lateral sclerosis

Interventions

Once daily perampanel with dose escalation from 2mg to 8mg.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients (male or female) who are aged over 20 years old. 2. Patients who are diagnosed as definite or probalble (including "laboratory supported-") ALS based on the revised El Escorial diagnostic criteria or the Awaji criteria. 3. Patients who are able to submit written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients who are expected to show rapid symptomatic progression. 2. Patients with severe complications. 3. Patients with malignancy. 4. Patients with severe psychiatric symptoms. 5. Patients who participated in another cliniccal trial within 12 weeks. 6. Patients who are judged to be ineligible for study entry by the investigators.

Design outcomes

Primary

Measure	Time frame
Persistency rate of perampanel at week 48	—

Countries

Japan

Contacts

Public ContactKanai Kazuaki

Juntendo University School of Medicine Department of Neurology

kzkanai@juntendo.ac.jp03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026